Leucine

Leucine

SCHEMBL1997233

CC(C)C[C@H](N)C(=O)O.CC(C)[C@H](N)C(=O)O.C[C@H](N)C(=O)O.NCC(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.41
SLC1A3 P43003 3/20 0.35
SLC1A2 P43004 3/20 0.35
SLC1A1 P43005 2/20 0.33
REN P00797 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30
DPP7 Q9UHL4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL4611635 1.00 SLC7A5 (0.41) SLC7A5SLC1A3SLC1A2SLC1A1REN
Leucine SCHEMBL1997232 1.00 SLC7A5 (0.41) SLC7A5SLC1A3SLC1A2SLC1A1REN
Leucine SCHEMBL4663987 0.98 SLC7A5 (0.43) SLC7A5SLC1A3SLC1A2SLC1A1REN
Leucine SCHEMBL4612139 0.98 SLC7A5 (0.43) SLC7A5SLC1A3SLC1A2SLC1A1REN
Leucine SCHEMBL27683632 0.98 SLC7A5 (0.43) SLC7A5SLC1A3SLC1A2SLC1A1REN
Leucine SCHEMBL6376065 0.98 SLC7A5 (0.43) SLC7A5SLC1A3SLC1A2SLC1A1REN
Leucine SCHEMBL27686470 0.95 SLC7A5 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL14966502 0.95 SLC7A5 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL14966504 0.95 SLC7A5 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL7110075 0.94 SLC7A5 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2337577-A1 USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS The Administrators of the Tulane Educational Fund (US) 2011-06-29 EP disclosed
WO-2010036936-A2 USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2010-04-01 WO disclosed
US-6962904-B1 Elastin peptide analogs and uses thereof CONNECTIVE TISSUE IMAGINEERING (US) 2005-11-08 US disclosed
US-6809075-B1 Elastin peptide analogs and uses of same incombination with skin enhancing agents CONNECTIVE TISSUE IMAGINEERING LLC 2004-10-26 US disclosed
US-6794362-B1 TOPICAL COSMETIC APPLIED AS EMULSION, LOTION, SPRAY, POWDER, OINTMENT, CREAM, INCREASES SKIN'S TURGOR CONNECTIVE TISSUE IMAGINEERING LLC 2004-09-21 US disclosed
US-6506731-B1 Peptide or peptide-like compound(s) of the present invention appear to aid the elasticity and/or turgor of the skin CONNECTIVE TISSUE IMAGINEERING LLC 2003-01-14 US disclosed